JP5568876B2 - Teeth demineralization inhibitor and oral composition - Google Patents

Description

  The present invention suppresses the amount of acid produced from biofilms by cariogenic bacteria, and is excellent in tooth demineralization inhibitor capable of remarkably suppressing tooth demineralization, and tooth demineralization inhibiting effect, and also has formulation stability. The present invention relates to a composition for oral cavity which is good and can effectively prevent the onset and progression of dental caries by improving the acid resistance performance of tooth.

  When tooth enamel and dentin are exposed to acids produced by oral bacteria, they lose mineral components and develop or progress caries. However, if there is no clear defect in the caries surface layer and only the mineral ions inside the caries are eluted, the mineral ions are supplied to the inside of the initial caries by appropriate oral care and remineralized. It is known to improve to the original state by a reaction called

  Therefore, in order to prevent the onset or progression of caries, it is desired to further improve the acid resistance performance of the tooth, and as a conventional technique, a technique utilizing a component that enhances the acid resistance effect of the tooth, Development of germicides for cariogenic bacteria that are produced.

  Examples of such techniques include tooth surface coating techniques using phosphate esters or polymers (Patent Documents 1 and 2; JP-A-05-320032 and JP-A-2005-200345), and dental protection using aluminum and fluoride. Techniques (Patent Documents 3 and 4; Japanese Patent Laid-Open Nos. 05-155746 and 06-298632) have been proposed, but it is difficult to control the adsorptive power to the tooth surface and long-term holding. There is a problem. Further, tooth enhancement technology using tea extract (Patent Document 5; JP 2005-29496 A), acid resistance technology using zinc (Patent Document 6; JP 11-228368 A), etc. have been proposed. In this technique, since a biofilm is present at a site where caries occurs, sufficient medicine cannot reach the tooth surface.

  On the other hand, from the viewpoint of sterilization of oral bacteria biofilms, a technique incorporating triclosan (Patent Documents 7 and 8; Japanese Patent Laid-Open Nos. 06-287120 and 02-001402) and benzalkonium chloride were blended. Techniques (Patent Document 9; Japanese Patent Laid-Open No. 11-246314), techniques incorporating chlorohexidine (Patent Document 10; Japanese Patent Laid-Open No. 20-023337), and the like have been proposed, but these are particularly effective against floating bacteria. Although it is high, it cannot be said that sufficient bactericidal power to bacteria in biofilm is exhibited. Technology for enhancing bactericidal activity (Patent Documents 11 to 13; Patent No. 3717960, Patent No. 3803695, Patent No. 3968131) and Technology for enhancing the retention of bactericides in the oral cavity (Patent Document 14; Patent No. 1) No. 3429065) has also been proposed, but no medicinal effect on the grown biofilm has been shown. Isopropylmethylphenol, which is known to penetrate and biocide into biofilms, has a high bactericidal effect against periodontogenic bacteria, but is not effective against cariogenic bacteria and produces acid. It is difficult to suppress Noh satisfactorily.

  Accordingly, there is a demand for a new technique capable of suppressing acid produced from a biofilm caused by cariogenic bacteria and preventing the onset or progression of caries.

JP 05-320032 A JP 2005-200345 A JP 05-155746 A Japanese Patent Laid-Open No. 06-298632 JP 2005-29496 A Japanese Patent Laid-Open No. 11-228368 Japanese Patent Laid-Open No. 06-287120 Japanese Patent Laid-Open No. 02-001402 JP-A-11-246314 Japanese Patent Laid-Open No. 20-023337 Japanese Patent No. 3717960 Japanese Patent No. 3803695 Japanese Patent No. 3968131 Japanese Patent No. 3429065

  The present invention has been made in view of the above circumstances, and effectively suppresses the acid produced from the biofilm of protoplasts in the oral cavity and suppresses the decalcification of teeth excellent in suppressing the decalcification of teeth. And a composition for oral cavity that has an excellent anti-decalcification effect on teeth, has good formulation stability, and can improve the acid resistance of the tooth and prevent the onset or progression of dental caries The purpose is to do.

  As a result of intensive studies to achieve the above object, the present inventors have combined (A) arabitol and (B) isopropylmethylphenol from a biofilm of cariogenic bacteria by combining them at a specific ratio. It is possible to obtain an excellent dental demineralization inhibitor that can suppress the amount of acid produced and greatly suppress the decalcification of teeth due to acid, and further, the oral composition containing this demineralization inhibitor is The inventors have found that the acid produced from the biofilm of cariogenic bacteria is excellent in suppressing the decalcification of teeth and the storage stability is also improved, and the present invention has been made.

  In the present invention, by blending arabitol in an appropriate ratio in combination with isopropylmethylphenol, these components act synergistically, and the sterilizing effect derived from isopropylmethylphenol is unexpectedly improved and cariogenic. High bactericidal effect on fungi, and even if a biofilm is formed by cariogenic bacteria, the drug barrier function is lowered and the high effect of suppressing acid production produced by cariogenic bacteria Is demonstrated. Furthermore, by blending the tooth demineralization inhibitor of the present invention into a liquid oral composition, and more preferably by incorporating a surfactant, the tooth demineralization inhibitory effect is excellent and discoloration even after long-term storage. The present inventors have found that good storage stability without causing cloudiness or white turbidity can be obtained, and have made the present invention. Such a special effect of the present invention is also clear from the experimental results of Examples described later, lacking any component of isopropylmethylphenol and arabitol, or xylitol of other sugar alcohols instead of arabitol. When sorbitol or the like is blended, or when the blending ratio of both components is inappropriate, either effect is inferior and the object of the present invention cannot be achieved.

Accordingly, the present invention, (A) and arabitol, consists of a (B) isopropyl methyl phenol, (A) / weight ratio of (B) is Ri 50-400 der, 1 is the content of the component (A) The tooth demineralization inhibitor characterized by 30 mass% and content of (B) component being 0.01-0.2 mass% , and comprising said tooth demineralization inhibitor An oral composition is provided.

  The tooth demineralization inhibitor of the present invention has a high effect of suppressing acid production from biofilms by cariogenic bacteria, and a biofilm is formed, which significantly reduces tooth demineralization by cariogenic bacteria. Can be suppressed. The composition for oral cavity containing the demineralization inhibitor for teeth of the present invention is excellent in the demineralization inhibitory effect of the tooth, has good formulation stability, and is effective in effectively preventing the onset and progression of dental caries. It is.

  The tooth demineralization inhibitor of the present invention is characterized by comprising (A) arabitol and (B) isopropylmethylphenol.

Arabitol is a sugar alcohol obtained by reducing D-arabinose and L-lyxose. Although arabitol includes D (+)-arabitol and L (-)-arabitol, each may be used alone or in combination of two kinds.
As arabitol, commercially available products such as D (+)-arabitol and L (−)-arabitol manufactured by Wako Pure Chemical Industries, Ltd., Kanto Chemical Co., and Sigma can be used.

  As isopropylmethylphenol, for example, isopropylmethylphenol commercially available from Osaka Kasei Co., Ltd. can be used.

(A) / (B) is 50-400 as a compounding ratio (mass ratio) of the arabitol of (A) component and (B) isopropylmethylphenol. If (A) / (B) is less than 10, the bactericidal effect on the caries biofilm is reduced and decalcification proceeds, and if it exceeds 700, the bactericidal activity of isopropylmethylphenol is reduced, resulting in a decalcification inhibitory effect. Inferior.

The composition for oral cavity of this invention mix | blends the above-mentioned tooth demineralization inhibitor.
Here, the content of arabitol as the component (A) is preferably 1 to 30% (mass%, the same applies hereinafter) of the whole composition, particularly 2.5 to 30%, and particularly has a high effect of suppressing the decalcification of teeth. 4 to 20% is more preferable. If the blending amount is less than 1%, the effect of suppressing the decalcification of teeth is not sufficiently exhibited . If it exceeds 30%, the bactericidal activity of isopropylmethylphenol will decrease, or it will be colored after storage and good storage stability will not be obtained .

The blending amount of the component (B), isopropylmethylphenol, is preferably 0.01 to 0.2% of the whole composition, and particularly preferably 0.03 to 0.1% in terms of decalcification inhibiting effect and solubility. If the blending amount is less than 0.01%, tooth calcification proceeds because sterilization of cariogenic bacteria is not sufficient . If it exceeds 0.2%, the solubility is lowered and the orientation is generated in the composition .

The composition of the present invention preferably further contains (C) a surfactant.
As the surfactant of component (C), any surfactant can be used without particular limitation as long as it is usually blended in a composition for oral cavity. Anionic surfactant, nonionic surfactant, cationic surfactant, amphoteric surfactant, etc. However, anionic surfactants and nonionic surfactants can be suitably blended.

  Examples of surfactants include anionic surfactants such as N-acyl amino acid salts, α-olefin sulfonates, N-acyl sulfonates, alkyl sulfates, sulfates of glycerin fatty acid esters, polyoxyethylene alkyl ethers, Nonionic surfactants such as polyoxyethylene-polyoxypropylene block copolymer, polyoxyethylene hydrogenated castor oil, polyoxyethylene ether of glycerin ester, sucrose fatty acid ester, and alkylolamide can be used. These surfactants can be used alone or in combination of two or more.

  As the anionic surfactant, N-acylamino acid salts, α-olefin sulfonates, alkyl sulfates and the like are preferably used particularly from the viewpoint of versatility. Specifically, sodium lauroyl sarcosine, sodium α-olefin sulfonate having 10 to 16 carbon atoms in the alkyl chain, sodium lauryl sulfate and the like can be used in terms of foamability and hard water resistance.

  As the nonionic surfactant, polyoxyethylene alkyl ether, polyoxyethylene hydrogenated castor oil, alkylolamide, sorbitan fatty acid ester and the like are preferably used particularly from the viewpoint of versatility. Specifically, polyoxyethylene alkyl ether having 14 to 18 carbon atoms in the alkyl chain, 15 to 30 ethylene oxide average addition moles, polyoxyethylene hydrogenated castor oil having 40 to 100 ethylene oxide average addition moles, An alkylolamide having 12 to 14 carbon atoms in the alkyl chain, a sorbitan fatty acid ester having 12 to 18 carbon atoms in the fatty acid, a polyoxygen having 16 to 18 carbon atoms in the fatty acid and an average ethylene oxide addition mole number of 10 to 40 Ethylene sorbitan fatty acid ester and the like can be used.

  The blending amount of the component (C) surfactant is preferably 0.05 to 2% of the whole composition, and particularly 0.2 to 1% in terms of achieving both a decalcification inhibitory effect and solubility. If the blending amount is less than 0.05%, isopropylmethylphenol may be insolubilized, and if it exceeds 2%, the sterilizing activity of isopropylmethylphenol is lowered, and a satisfactory decalcification inhibiting effect may not be exhibited.

  The liquid oral composition of the present invention preferably further contains a fluoride, particularly sodium fluoride and / or sodium monofluorophosphate. In the present invention, the drug barrier function of the biofilm is reduced due to the combined effect of arabitol and isopropylmethylphenol, so that fluoride as a caries preventive component can easily penetrate into the biofilm. The effect of suppressing the decalcification of ash is further improved.

  The compounding amount of the fluoride is preferably 100 to 500 ppm of the whole composition as fluorine because it can be used for infants who have a possibility of aspiration and children whose maturation of permanent tooth enamel is not advanced. If the amount is less than 100 ppm, the deashing suppression effect may not be improved. If the amount exceeds 500 ppm, the concentration is not recommended by a dental specialist.

  The oral composition of the present invention is preferably prepared into a liquid preparation from the viewpoint of effectiveness and safety, and can be prepared into a dosage form such as a mouthwash, a dentifrice such as a liquid dentifrice, and a coating agent. It is suitably prepared as a mouthpiece.

  In addition to the above components, the oral composition of the present invention can be blended with known components, if necessary, within a range that does not interfere with the effects of the present invention, depending on the dosage form of the composition. As optional components, for example, binders, thickeners, sweeteners, preservatives, fragrances, medicinal ingredients, solvents such as water and the like can be blended within a range that does not impair the effects of the present invention. Although the specific example of an arbitrary component is shown below, the component which can be mix | blended with the composition of this invention is not restrict | limited to these.

  Examples of the binder include pullulan, gelatin, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, gum arabic, guar gum, locust bean gum, polyvinyl alcohol, polyvinylpyrrolidone, etc. 0.01 to 2%.

  As the thickening agent, a polyhydric alcohol or the like is blended, and a sugar alcohol other than arabitol may be blended within a range that does not impair the effect of arabitol. For example, sorbit, 70% sorbit, propylene glycol, butylene glycol, glycerin, polyethylene glycol and the like can be mentioned. The above thickener can be usually blended in an amount of 1 to 50% based on the whole preparation. In addition, the compounding amount of the sugar alcohol is preferably in the range of 1 to 60%, particularly 5 to 40% in total with the component (A) arabitol.

  Examples of the sweetening agent include saccharin sodium, stevioside, neohesperidin hydrochalcone, glycyrrhizin, perilartin, p-methoxycinnamic aldehyde, thaumatin, palatinose, erythritol, maltitol, xylitol and the like.

  Examples of the preservative include paraoxybenzoic acid esters such as methyl paraben, ethyl paraben, and butyl paraben, benzoic acid or a salt thereof (sodium salt, etc.), ethylenediaminetetraacetate, benzalkonium chloride, and the like.

  As a fragrance, for example, essential oils such as peppermint and spearmint, fruit-based essences such as lemon and strawberry, l-menthol, carvone, eugenol, anethole, linalool, limonene, oximen, cineol, n-decyl alcohol, citronellol, crocodile, Perfume materials such as α-terpineol, methyl salicylate, thymol, rosemary oil, sage oil, perilla oil, lemon oil and orange oil are suitable.

  Furthermore, as an active ingredient, in addition to isopropylmethylphenol and further fluoride, other medicinal ingredients, specifically, bactericidal or antibacterial agents such as chlorohexidine, triclosan, cetylpyridinium chloride, zinc gluconate and zinc citrate, condensed phosphorus Calculus preventives such as acid salts and ethane hydroxydiphosphonates, anti-inflammatory agents such as tranexamic acid and dipotassium glycyrrhizin, coating agents such as hydroxyethylcellulose dimethyldiallylammonium chloride, enzyme agents such as dextranase and mutanase, chloride Astringents such as sodium and aluminum lactate, and hypersensitivity inhibitors such as potassium nitrate can be used within a pharmaceutically acceptable range.

  In the composition of the present invention, water, a lower alcohol having 3 or less carbon atoms such as ethanol, propanol and the like can be blended as a solvent. The content of the solvent is usually 30 to 95%, and more preferably 50 to 90%. Content of a lower alcohol is 0 to 50% of range, and 0 to 10% is more preferable.

  It is preferable that pH of the composition for oral cavity of this invention is 5-8, and it can adjust pH using a pH adjuster as needed. Examples of pH adjusters include phosphoric acid or salts thereof (sodium phosphate, sodium hydrogen phosphate, etc.), citric acid or salts thereof (sodium citrate, etc.), malic acid or salts thereof, gluconic acid or salts thereof, maleic acid or The salt, succinic acid or its salt, glutamic acid or its salt, lactic acid, hydrochloric acid, acetic acid, nitric acid, sodium hydroxide, potassium hydroxide, etc. can be used in the range which does not impair the effect of this invention.

  EXAMPLES Hereinafter, although an experimental example, an Example, and a comparative example are shown and this invention is demonstrated concretely, this invention is not restrict | limited to the following Example. In the following examples,% indicates a mass percentage.

  The main raw materials used were D (+)-arabitol (manufactured by Wako Pure Chemical Industries, Sigma), L (-)-arabitol (manufactured by Kanto Chemical Co., Ltd., Junsei Chemical Co., Ltd.), xylitol (rocket / fluele). Co., Ltd.), Palatinite (Mitsui Sugar Co., Ltd.), Erythritol (Mitsubishi Chemical Foods Co., Ltd.), Sorbitol (Towa Kasei Kogyo Co., Ltd.), Isopropylmethylphenol (Osaka Kasei Co., Ltd.), Sodium Fluoride (Stella Chemifa Co., Ltd.), Sodium monofluorophosphate (manufactured by Rhodia Nikka), polyoxyethylene hydrogenated castor oil (40) (HCO40; manufactured by Nikko Chemicals), polyoxyethylene hydrogenated castor oil (60) (HCO60; manufactured by Nikko Chemicals), poly Oxyethylene hydrogenated castor oil (80) (RCW80; manufactured by Aoki Yushi Kogyo Co., Ltd.), polyoxyethylene hydrogenated castor oil ( 00) (HCO 100; manufactured by Nikko Chemicals), polyoxyethylene cetyl ether (20) (EMALEX 120; manufactured by Nippon Emulsion), polyoxyethylene stearyl ether (30) (EMALEX 630; manufactured by Nippon Emulsion), glycerin (85%, Sakamoto Yakuhin Kogyo Co., Ltd.), propylene glycol (Asahi Glass Co., Ltd.), ethanol (Nihon Alcohol Sales Co., Ltd.).

[Experimental Example 1] Storage Stability Test Liquid oral compositions (compositions of Examples and Comparative Examples) having the compositions shown below were prepared by a conventional method and then injected into a PET container. The stability of the composition after standing for 1 month in a thermostatic chamber (50 ° C.) was visually observed and evaluated according to the following criteria.

Appearance stability evaluation criteria;
○: Almost no change compared to the initial product △: Increased degree of coloring (yellow) ×: White turbidity or sediment was observed

[Experimental Example 2] Demineralization suppression evaluation of human enamel sample under biofilm Preparation of human enamel sample;
The enamel portion of the extracted human tooth polished with carborundum (HP13; manufactured by Matsukaze Co., Ltd.) and paper cone (SHARP-MINI; manufactured by Oki Chemical Co., Ltd.) was cut into approximately 5 mm square. A human enamel sample was prepared by coating with nail polish except for the 2 × 2 mm window.

Biofilm production and drug treatment on human enamel samples;
3% by mass of Todd Hewitt sterilized by autoclaving at 121 ° C. for 15 minutes with 40 μL of a bacterial solution of Streptococcus mutans ATCC25175 strain that has been passaged (freeze-stored) at Oral Care Research Laboratories, Lion Corp. Broth (Becton & Dickinson) culture solution (THB) was added to 4 mL, and anaerobic culture (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% hydrogen) was performed overnight at 37 ° C. After the culture, 300 μL was collected from the bacterial solution, added to 30 mL of THB medium, and further cultured overnight.
After re-culture, the bacterial solution was centrifuged (10,000 rpm, 10 min), and the supernatant was discarded. After adding and resuspending the THB medium to the sediment (bacteria), the number of bacteria is 1 × 10 ⁷ cells / mL in the culture tank A (diameter 90 mm × height 190 mm) whose liquid volume is maintained at 300 mL. The suspension was inoculated so as to be cultivated overnight at 37 ° C. under anaerobic conditions (95 vol% nitrogen, 5 vol% carbon dioxide) while stirring with a stirrer (rotating at about 100 rpm). Thereafter, the culture solution is supplied from the culture vessel B containing 1,000 mL of THB culture solution containing 0.5% sucrose to the culture vessel A at a rate of 100 mL / h, and cultured from the culture vessel A at the same rate. The liquid was drained. This process was performed continuously. A human enamel sample was mounted on the turntable (rotating at about 80 rpm) in the culture tank A so that the window portion was on the upper surface, and a biofilm was formed on the window portion.

  The culture by the above method was carried out for 7 days, and the following drug treatment was carried out for the latter 5 days. That is, twice a day, a human enamel sample with a biofilm attached was taken out of the culture tank, transferred to a petri dish (diameter 35 mm × height 14 mm), and 5 g of a liquid oral composition (in the examples and comparative examples shown below). Immediately after the preparation of the liquid oral composition and a product stored at 50 ° C. for 1 month (1M) as a sample) were immersed for 20 seconds. Then, after washing once with 5 g of physiological saline (manufactured by Otsuka Pharmaceutical Co., Ltd.), it was returned to the culture tank again. This operation was performed 10 times in total.

Demineralization inhibition evaluation of human enamel samples;
After completion of the culture, the human enamel sample was immersed in a sufficient amount of acetone, and the nail polish covering the biofilm and the sample was removed. Using a QLF (Quantitative Light-Induced Fluorescence; Inspector Research Systems BV) system that can quantify initial caries by measuring changes in the fluorescence intensity of teeth, the ΔF value of the window part (average when compared with the healthy part) The amount of change in fluorescence intensity (shown here as a positive value) was measured, and the degree of demineralization was quantified. The average value of each example n = 3 was calculated and evaluated according to the following criteria. The larger the ΔF value, the more deashing is progressing, and the smaller the ΔF value, the higher the deashing suppression effect.

Evaluation criteria for the degree of decalcification;
ΔF value: less than 10% A
10% or more and less than 15% B
15% or more but less than 20% C
20% or more and less than 25% D
25% or more and less than 30% E
More than 30% or axillary f

[Example 1 ]
D (+)-arabitol (manufactured by Sigma) 4.0
Isopropyl methylphenol 0.05
Polyoxyethylene hydrogenated castor oil (60) 0.2
Propylene glycol 3.0
Glycerin 10.0
Saccharin sodium 0.3
Sodium dihydrogen phosphate 0.6
Fragrance 0.2
Methylparaben 0.3
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 7.1

[Example 2 ]
D (+)-arabitol (manufactured by Sigma) 15.0
Isopropyl methylphenol 0.05
Polyoxyethylene hydrogenated castor oil (60) 0.3
Propylene glycol 5.0
Glycerin 8.0
Saccharin sodium 0.5
Sodium dihydrogen phosphate 0.5
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 6.3

[Example 3 ]
D (+)-arabitol (manufactured by Sigma) 30.0
Isopropylmethylphenol 0.08
Polyoxyethylene hydrogenated castor oil (60) 0.5
Propylene glycol 5.0
Glycerin 10.0
Saccharin sodium 0.7
Sodium monohydrogen phosphate 0.7
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Hydrochloric acid
Distilled water remaining
Total 100%
pH 6.0

[Example 4 ]
L (-)-arabitol (made by Junsei Kagaku) 25.0
Isopropylmethylphenol 0.2
Polyoxyethylene hydrogenated castor oil (80) 2.0
Propylene glycol 3.0
Glycerin 8.0
Saccharin sodium 0.5
Sodium dihydrogen phosphate 0.5
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 5.5

[Example 5 ]
D (+)-arabitol (manufactured by Wako Pure Chemical Industries, Ltd.) 10.0
Isopropyl methylphenol 0.05
Polyoxyethylene hydrogenated castor oil (60) 0.5
Propylene glycol 3.0
Saccharin sodium 0.5
Sodium dihydrogen phosphate 0.5
Fragrance 0.1
Methylparaben 0.3
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 6.4

[Example 6 ]
D (+)-arabitol (manufactured by Sigma) 4.0
Isopropyl methylphenol 0.05
Polyoxyethylene hydrogenated castor oil (60) 0.2
Sodium fluoride 0.05
Propylene glycol 3.0
Glycerin 10.0
Saccharin sodium 0.3
Sodium dihydrogen phosphate 0.6
Fragrance 0.2
Methylparaben 0.3
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 7.1

[Example 7 ]
D (+)-arabitol (manufactured by Sigma) 15.0
Isopropyl methylphenol 0.05
Polyoxyethylene hydrogenated castor oil (60) 0.3
Sodium fluoride 0.05
Propylene glycol 5.0
Glycerin 8.0
Saccharin sodium 0.5
Sodium dihydrogen phosphate 0.5
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 6.3

[Example 8 ]
D (+)-arabitol (manufactured by Sigma) 30.0
Isopropylmethylphenol 0.08
Polyoxyethylene hydrogenated castor oil (60) 0.5
Sodium monofluorophosphate 0.15
Propylene glycol 5.0
Glycerin 10.0
Saccharin sodium 0.7
Sodium monohydrogen phosphate 0.7
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Hydrochloric acid
Distilled water remaining
Total 100%
pH 6.0

[Example 9 ]
L (-)-arabitol (made by Junsei Kagaku) 25.0
Isopropylmethylphenol 0.2
Polyoxyethylene hydrogenated castor oil (80) 2.0
Sodium fluoride 0.025
Propylene glycol 3.0
Glycerin 8.0
Saccharin sodium 0.5
Sodium dihydrogen phosphate 0.5
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 5.5

[Comparative Example 1]
D (+)-arabitol (manufactured by Sigma) 0.4
Isopropylmethylphenol 0.1
Polyoxyethylene hydrogenated castor oil (60) 0.5
Propylene glycol 5.0
Glycerin 10.0
Saccharin sodium 0.5
Sodium dihydrogen phosphate 0.5
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 6.3

[Comparative Example 2]
D (+)-arabitol (manufactured by Sigma) 30.0
Isopropylmethylphenol 0.035
Polyoxyethylene hydrogenated castor oil (60) 0.5
Propylene glycol 5.0
Glycerin 10.0
Saccharin sodium 0.5
Sodium dihydrogen phosphate 0.5
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 6.3

[Comparative Example 3]
Isopropylmethylphenol 0.2
Polyoxyethylene hydrogenated castor oil (60) 0.5
Propylene glycol 5.0
Glycerin 10.0
Saccharin sodium 0.5
Sodium dihydrogen phosphate 0.5
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 6.3

[Comparative Example 4]
D (+)-arabitol (manufactured by Sigma) 10.0
Polyoxyethylene hydrogenated castor oil (60) 0.5
Propylene glycol 5.0
Glycerin 10.0
Saccharin sodium 0.5
Sodium dihydrogen phosphate 0.5
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 6.3

[Comparative Example 5]
L (-)-arabitol (made by Junsei Kagaku) 10.0
Polyoxyethylene hydrogenated castor oil (60) 0.5
Propylene glycol 5.0
Glycerin 10.0
Saccharin sodium 0.5
Sodium dihydrogen phosphate 0.5
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 6.3

[Comparative Example 6]
Xylitol 10.0
Isopropyl methylphenol 0.05
Polyoxyethylene hydrogenated castor oil (60) 0.5
Propylene glycol 5.0
Glycerin 10.0
Saccharin sodium 0.5
Sodium dihydrogen phosphate 0.5
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 6.3

[Comparative Example 7]
Palatinit 10.0
Isopropyl methylphenol 0.05
Polyoxyethylene hydrogenated castor oil (60) 0.5
Propylene glycol 5.0
Glycerin 10.0
Saccharin sodium 0.5
Sodium dihydrogen phosphate 0.5
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 6.3

[Comparative Example 8]
Erythritol 10.0
Isopropyl methylphenol 0.05
Polyoxyethylene hydrogenated castor oil (60) 0.5
Propylene glycol 5.0
Glycerin 10.0
Saccharin sodium 0.5
Sodium dihydrogen phosphate 0.5
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 6.3

[Comparative Example 9]
Sorbitol 10.0
Isopropyl methylphenol 0.05
Polyoxyethylene hydrogenated castor oil (60) 0.5
Propylene glycol 5.0
Glycerin 10.0
Saccharin sodium 0.5
Sodium dihydrogen phosphate 0.5
Fragrance 0.4
Methylparaben 0.4
Ethanol 5.0
Sodium hydroxide
Distilled water remaining
Total 100%
pH 6.3

  The compositions and evaluation results of these examples and comparative examples are summarized in Tables 1 to 4. In the table, IPMP is an abbreviation for isopropylmethylphenol, POE is an abbreviation for polyoxyethylene, NaF is sodium fluoride, and MFP is sodium monofluorophosphate. The numerical value in () in the component (C) represents the average number of moles of ethylene oxide added.

Claims (6)

(A) and arabitol, (B) consists isopropyl methylphenol, (A) / mass ratio is 50-400 der of (B) is, the content of the component (A) 1 to 30 wt%, (B ) A demineralization inhibitor for teeth, wherein the content of the component is 0.01 to 0.2% by mass .   An oral composition comprising the dental demineralization inhibitor according to claim 1. Furthermore, 0.05-2 mass% of (C) surfactant is contained, The composition for oral cavity of Claim 2 characterized by the above-mentioned. (C) The surfactant is sodium lauroyl sarcosine, sodium α-olefin sulfonate having 10 to 16 carbon atoms in the alkyl chain, sodium lauryl sulfate, 14 to 18 carbon atoms in the alkyl chain, and the average added mole number of ethylene oxide. 15 to 30 polyoxyethylene alkyl ether, polyoxyethylene hydrogenated castor oil having an average ethylene oxide addition mole number of 40 to 100, alkylol amide having 12 to 14 carbon atoms in the alkyl chain, and 12 to 18 carbon atoms in the fatty acid 4. The sorbitan fatty acid ester of claim 1, wherein the fatty acid is one or more selected from polyoxyethylene sorbitan fatty acid esters having 16 to 18 carbon atoms and an average number of moles of ethylene oxide added of 10 to 40. The composition for oral cavity of description.   Furthermore, fluoride is contained, The composition for oral cavity of any one of Claim 2 thru | or 4 characterized by the above-mentioned.   The composition for oral cavity according to any one of claims 2 to 5, which is prepared as a liquid preparation.